Treatment With Nutritional Eating Plan and Dietary Fibers in Adult Patients With HIV/AIDS
- Conditions
- Signs and Symptoms, DigestiveHIVDietary ModificationDyslipidemia
- Interventions
- Dietary Supplement: Maltodextrin (placebo for symbiotic)Dietary Supplement: SymbioticBehavioral: Nutritional intervention
- Registration Number
- NCT02180035
- Lead Sponsor
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Brief Summary
To evaluate if nutritional treatment with nutritional supplementation of dietary fiber reduces cholesterol levels and triglycerides (dyslipidemia) in patients with HIV/AIDS receiving antiretroviral therapy (HAART).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 290
- HIV-infected patients
- Adults (≥ 19 years old)
- On highly active antiretroviral therapy (HAART)
- Pregnancy
- Breastfeeding
- Opportunistic disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Maltodextrin & Nutritional intervention Nutritional intervention Maltodextrin (placebo for symbiotic) 6g sachet twice daily for 6 months, dietary intervention and nutritional counseling. Symbiotic & Nutritional intervention Nutritional intervention Symbiotic (dietary fibers + probiotic bacteria) 6g sachet twice daily for 6 months, dietary prescription and nutritional counseling Maltodextrin & Nutritional intervention Maltodextrin (placebo for symbiotic) Maltodextrin (placebo for symbiotic) 6g sachet twice daily for 6 months, dietary intervention and nutritional counseling. Symbiotic & Nutritional intervention Symbiotic Symbiotic (dietary fibers + probiotic bacteria) 6g sachet twice daily for 6 months, dietary prescription and nutritional counseling
- Primary Outcome Measures
Name Time Method Seric lipid levels Baseline, Week 24 Changes from baseline in total cholesterol, triglycerides, HDL-C and LDL-C.
- Secondary Outcome Measures
Name Time Method Gastrointestinal symptoms Baseline, Week 24 Assessment of the presence of gastrointestinal symptoms (nausea and/or vomiting, dyspepsia, heartburn, diarrhea, flatulence and constipation), associated or not with antiretrorival therapy, before and after intervention to verify their effectiveness in reducing these symptoms.
Body composition Baseline, Week 24 Changes from baseline in total body fat percentage, percentage of fat in the trunk, percentage of fat in the arms, percentage of fat in the legs and lean body mass percentage.
Anthropometric measures Baseline, Week 24 Changes from baseline in weight, waist circumference, abdominal circumference, waist-to-hip ratio and Body Mass Index (BMI).
Fasting blood glucose Baseline, Week 24 Changes from baseline in fasting blood glucose.
Adherence to the nutritional intervention and nutritional appointments Baseline, Week 24 Assessment of dietary intake modification after intervention and patient's return to nutritional appointments.
Trial Locations
- Locations (1)
Outpatient Infectoparasitary Diseases, Hospital das Clinicas, Federal University of Goiás
🇧🇷Goiânia, Goiás, Brazil